|Articles|July 1, 2005

Oracea phase 3 clinical trials show 'highly significant' results

Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME